Pipeline - Roche
文章推薦指數： 80 %
Description/ Summary: Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling ... MediaInvestorsCareersAboutRocheAboutRocheStrategyBusinessSustainabilityLeadershipGovernanceHistorySolutionsSolutionsFocusareasPharmasolutionsDiagnosticssolutionsPipelineInnovationInnovationTeam&structureInnovationprocessEthicalstandardsPartneringStoriesProductDevelopmentPortfolioPipelineDiagnosticsCurrentVersionSeeChangesFiltercompoundgenericnametradenameindicationphase 123fexpected filingareaproductnamedescriptionmarketLastupdate:21stofJuly2022DownloadsRocheGroupPharmaceuticalspipelinePDFRocheGroupDiagnosticspipelinePDFRocheGroupDevelopmentpipelinePDFGenentechPipelineOurR&Dactivitiesarefocusedonapplyingexcellentsciencetodiscoveranddeveloppotentialnewmedicineswiththegoalofbecomingfirst-in-classorbest-in-classtherapeutics.Discovermore
延伸文章資訊
- 1Development Pipeline | CHUGAI PHARMACEUTICAL CO., LTD.
Chugai's development pipeline is categorized to Oncology, Neuroscience, Hematology, Ophthalmology...
- 2Clinical Development | CHUGAI PHARMACEUTICAL CO., LTD.
Chugai Pharmaceutical's own in-house development pipeline has one of the strongest line-ups in Ja...
- 3Chugai - Roche
As a drug manufacturer and a pioneer in biotechnological and pharmaceutical research, Chugai is a...
- 4Chugai Pharmaceutical Opens a North American Hub in New ...
20, 2015 /PRNewswire/ -- Today, Chugai Pharma USA Inc. (CPUSA), a wholly-owned ... and early clin...
- 5Pipeline scale and blockage inspection
Inheriting the research from the parent company – Chugai Technos Corporation in Japan, we would l...
